Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina

Frontiers in Virology

Virology

Dillon Betancourt¹  Glen N. Barber¹  Antonio E. Muruato²  Kathleen M. Voss³  Michael Gale³  Jennifer Tisoncik-Go³  Paul T. Edlefsen⁴  Solomon Wangari⁵  Eric E. Finn⁵  Richard F. Grant⁵  LaRene Kuller⁵  Naoto Iwayama⁵  Joel Ahrens⁵  Robert D. Murnane⁶  Megan A. O’Connor⁷  Thomas B. Lewis⁷  Deborah H. Fuller⁷ 

[1] Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, United States;Department of Immunology, School of Medicine, University of Washington, Seattle, WA, United States;Department of Immunology, School of Medicine, University of Washington, Seattle, WA, United States;Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA, United States;Washington National Primate Research Center, Seattle, WA, United States;Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States;Washington National Primate Research Center, Seattle, WA, United States;Washington National Primate Research Center, Seattle, WA, United States;Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, United States;Washington National Primate Research Center, Seattle, WA, United States;Department of Microbiology, School of Medicine, University of Washington, Seattle, WA, United States;

关键词: Zika virus;    nonhuman primate;    vaccine;    rVSV vector;    immune response;   

DOI  :  10.3389/fviro.2023.1108420

 received in 2022-11-26, accepted in 2023-02-07,  发布年份 2023

来源: Frontiers

【 摘 要 】

Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZIKV infection can result in fetal injury and congenital Zika syndrome (CZS). Development of an effective vaccine is imperative to protect against ZIKV vertical transmission and CZS. Recombinant Vesicular Stomatitis virus (rVSV) is a highly effective and safe vector for the delivery of foreign immunogens for vaccine purposes. Here, we evaluate an rVSV vaccine expressing the full length pre-membrane (prM) and ZIKV envelope (E) proteins (rVSVΔM-ZprME), shown to be immunogenic in murine models of ZIKV infection, for its capacity to induce immune responses in nonhuman primates. Moreover, we assess the efficacy of the rVSVΔM-ZprME vaccine in the protection of pigtail macaques against ZIKV infection. Administration of the rVSVΔM-ZprME vaccine was safe, but it did not induce robust anti-ZIKV T-cell responses, IgM or IgG antibodies, or neutralizing antibodies in most animals. Post ZIKV challenge, animals that received the rVSVΔM control vaccine lacking ZIKV antigen had higher levels of plasma viremia compared to animals that received the rVSVΔM-ZprME vaccine. Anti-ZIKV neutralizing Ab titers were detected in a single animal that received the rVSVΔM-ZprME vaccine that was associated with reduced plasma viremia. The overall suboptimal ZIKV-specific cellular and humoral responses post-immunization indicates the rVSVΔM-ZprME vaccine did not elicit an immune response in this pilot study. However, recall antibody response to the rVSVΔM-ZprME vaccine indicates it may be immunogenic and further developments to the vaccine construct could enhance its potential as a vaccine candidate in a nonhuman primate pre-clinical model.

【 授权许可】

Unknown   
Copyright © 2023 Tisoncik-Go, Voss, Lewis, Muruato, Kuller, Finn, Betancourt, Wangari, Ahrens, Iwayama, Grant, Murnane, Edlefsen, Fuller, Barber, Gale and O’Connor